What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
BioPharma Dive7d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...
FierceBiotech7d
Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
AMGN Stock Down Despite Strong Data From Obesity Drug Study
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
Eli Lilly and Novo Nordisk’s obesity moat just got stronger
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
pharmaphorum6d
Amgen's big reveal of obesity data falls a little flat
That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data ...